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Heme oxygenase-1 (HO-1) is a rate-limiting enzyme in heme
degradation, producing carbon monoxide (CO), which carries
potent antiproliferative and anti-inflammatory effects in the
vascular walls. Transcription of the HO-1 gene is regulated
by the length polymorphism of dinucleotide guanosine
thymine repeat (GT)n in the promoter region, which was
measured in this study to determine its association with
arteriovenous fistula (AVF) failure in Chinese hemodialysis
(HD) patients in Taiwan. L allele means (GT)nX30 and S allele
means (GT)no30. Therefore, there are two L alleles for L/L
genotype, one L and one S allele for L/S genotype, and two
S alleles for S/S genotype. Among the 603 HD patients who
were enrolled in this study, 178 patients had history of AVF
failure, while 425 patients did not. Significant associations
were found between AVF failure and the following factors
(hazard ratio): longer HD duration (1.004 month), lower
pump flow (0.993 ml/min), higher dynamic venous pressure
(1.010 mmHg), location of AVF on the right side (1.587 vs left
side) and upper arm (2.242 vs forearm), and L/L and L/S
genotypes of HO-1 (2.040 vs S/S genotype). The proportion
of AVF failure increased from 20.3% in S/S genotype and
31.0% in L/S genotype to 35.4% in L/L genotype (P¼ 0.011).
Relative incidences were 1/87.6 (1 episode per 87.6
patient-months), 1/129, and 1/224.9 for HD patients with
L/L, L/S, and S/S genotypes, respectively (Po0.002). The
unassisted patency of AVF at 5 years decreased significantly
from 83.8% (124/148) to 75.1% (223/297) and 69% (109/158)
in S/S, L/S, and L/L genotypes, respectively (Po0.0001). In
comparison with HD patients with S/S genotype, those
with L/L genotype had a higher prevalence of coronary
artery disease (29.1 vs 14.2%; P¼ 0.005). A longer length
polymorphism with (GT)n X30 in the HO-1 gene was
associated with a higher frequency of access failure and a
poorer patency of AVF in HD patients. The longer GT repeat
in the HO-1 promoter might inhibit gene transcription, and
consequently offset the CO-mediated protective effect
against vascular injury.
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In Taiwan, more than 85% of patients with end-stage renal
disease undergo maintenance hemodialysis (HD). A well-
functioning vascular access is necessary for HD, and long-
term technical survival is best for native arteriovenous fistula
(AVF), which accounts for a prevalence of more than 80% of
the vascular access in our patients. About 17–25% of HD
patient hospitalizations in the USA result from vascular
access complications, at a cost of US $1 billion annually.1
Failure of dialysis access can result from either inadequate
blood flow on account of stenosis of the venous outflow tract
or complete occlusion due to thrombosis.2 About 80–85% of
arteriovenous (AV) access failures come from AV access
thromboses, more than 80% of which result from AVF
stenoses.3 Decreased access flow (Qa) is associated with an
increased risk of access thrombosis. Qa less than 500 ml/min
was demonstrated to be predictive of poorer unassisted
patency of native AVF by variable pump flow-based Doppler
ultrasound method in our previous study.4 In addition to Qa,
some mechanical factors, such as the surgical skill, the
puncture technique, and the shear stress on vascular
endothelia, influence AVF patency. Several medical factors
have also been identified to be associated with AVF stenosis
in HD patients, including endothelial cell injury, stasis,
hypercoagulability, medications, and red cell mass.5 Many
factors lead to endothelial cell injury or dysfunction, such as
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oxidative stress, hyperhomocysteinemia, activated platelets,
tumor necrosis factor-a, calcium/phosphate deposition, and
pre-existing intimal hyperplasia. The pathological features of
stenosis of vascular access consist of intimal hyperplasia,
vascular smooth muscle cell (VSMC) proliferation in the
media with subsequent migration to intima, and excessive
accumulation of extracellular matrix.6 In spite of the above
findings, the causes for development of stenoses still remain
unknown in a significant proportion of HD patients. This
interindividual variation may relate to genetic differences
among patients. In this regard, AV fistula patency has been
reported to be associated with specific genotype polymorph-
isms of transforming growth factor b1 (TGF-b1)7 and
methylene tetrahydrofolate reductase (MTHFR).8
In addition to the above factors, the activity of heme
oxygenase-1 (HO-1) is another factor associated with higher
risk of developing some vascular diseases. HO-1, an enzyme
playing an important role in heme degradation, results in the
production of biliverdin, free iron, and carbon monoxide
(CO).9 This enzyme is associated with oxidative stress,
platelet activation, and VSMC proliferation, as VSMC
proliferation, migration, and extracellular matrix synthesis
may be regulated by its reaction product, CO.10 The human
HO-1 gene was located at chromosome 22q12, and a
(guanidinium thiocyanate (GT)n) dinucleotide repeat of
different length was identified in the proximal promoter
region.11 However, the actions of HO-1 are highly variable
and may reflect a role for HO-1 in maintaining tissue
homeostasis. Kaneda et al.12 and Chen et al.13 have shown
that the (GT)n repeat is highly polymorphic, and a longer
(GT)n repeat exhibits lower transcriptional activity and is
associated with susceptibility to coronary artery disease
(CAD). Chen et al.14 also showed that genetic variation
influencing HO-1 expression would interact with traditional
risk factors and contribute to the development of restenosis
after placement of coronary stents. However, little informa-
tion is available on the role of genetic background of HO-1 in
the development of AVF stenosis.
This study was designed to determine whether the length
polymorphism of the dinucleotide (GT)n repeats in the HO-1
gene promoter region would be an independent factor for
predicting patency of AVF in HD patients.
RESULTS
Patient characteristics
The demographic and clinical characteristics of the patients
are summarized in Table 1. A total of 603 patients were
enrolled in the study. Among them, 425 patients did not have
any episode of AV fistula failure, but 178 patients did.
Compared with HD patients without AV fistula failure, those
with AV fistula failure had a longer HD duration (89.2765.6
vs 62.5753.0 months, Po0.001), a higher prevalence of AV
fistula at the right upper extremity (32 vs 18.6%, Po0.001)
and upper arm (27 vs. 9.2%, Po0.001), higher dynamic
venous pressure (148.2729.5 vs 140.9729.9 mmHg,
Po0.001), lower prevalence of hypertension (45.5 vs 56%,
P¼ 0.019), and borderline higher prevalence of cardiovas-
cular disease (32.6 vs 24.9%, P¼ 0.05). The allele frequencies
of the dinucleotide length polymorphism (GT)n in the HO-1
gene promoter found in the studied individuals are shown in
Figure 1. The repeat numbers ranged from 16 to 39, with
(GT)23 and (GT)30 being the two most common alleles in our
study population (allele frequencies are 20.6% for (GT)23 and
30.1% for (GT)30). We assigned those with GT repeats X30
Table 1 | Clinical characteristics of HD patients by the presence of failure of AV fistula
Overall (n=603) No AVF failure (n=425) AVF failure (n=178) P-value
Male (%) 52.6 51.3 55.6 0.33
Age (years) 60.0714.5 59.8714.0 60.6715.8 0.57
HD duration (months) 70.3758.2 62.5753.0 89.2765.6 o0.001
Site of AV fistula
Right side (%) 22.6 18.6 32 o0.001
Left side (%) 77.4 81.4 68
Location of AV fistula
Upper arm (%) 14.4 9.2 27 o0.001
Forearm (%) 85.6 90.8 73
Survival of AV fistula (months) 56.5753.3 64.3752.9 38.1749.6 o0.001
Time between creation of AV fistula and
initial HD (months)
1.6474.21 1.7976.95 1.2973.87 0.368
Dynamic venous pressure under pump
flow at 250 ml/min (mmHg)
142.6729.9 140.9729.9 148.20729.5 o0.001
Maximal pump flow (ml/min) 271.9733.3 273.2734.4 268.8730.1 0.14
Hypertension (%) 52.9 56 45.5 0.019
Diabetes mellitus (%) 30.5 30.4 30.9 0.894
Cerebral infarction (%) 8.6 7.8 10.7 0.246
Peripheral arterial obstructive disease (%) 4.6 3.8 6.7 0.113
Coronary artery disease (%) 21.1 19.5 24.7 0.154
Cardiovascular disease (%) 27.2 24.9 32.6 0.054
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as allele class L (long) and those with GT repeats o30 as
allele class S (short) owing to two reasons. First, Yamada
et al.15 also defined an allele with the number of GT repeats
X30 as a long allele (class L) in the Japanese population,
which, like our Chinese population, is a part of eastern Asian
people. Second, the alleles with GT repeats X30 accounted
for about 50% of all the alleles of HD patients and controls in
our study. The genotype of the study individual was defined
as (1) class L/L if both allele lengths of GT repeats wereX30,
(2) class L/S if one GT repeat was X30 and the other was
o30, and (3) class S/S if both allele lengths of GT repeats
wereo30. Therefore, the case number in any genotype group
will not be too small to allow appropriate statistical analysis.
The distribution of allele and genotype classes did not differ
between whole HD patients and healthy controls (Table 2).
Association of HO-1 polymorphism with AV fistula failure in
HD patients
As shown in Table 2, the proportion of L allele frequency (57.3
vs 48.1%; P¼ 0.004) and the proportion of L/L genotype
frequency (31.5 vs 24%; P¼ 0.011) were significantly higher
in HD patients with AVF failure than in those without AVF
failure. With regard to the frequencies of HD patients with
AVF failure in different classes of genotypes, the proportion of
AVF failure increases from 20.3% in class S/S to 31.0% in class
L/S and 35.4% in class L/L (Table 3; P¼ 0.011).
Association of HO-1 polymorphism with comorbid vascular
diseases
In comparison with HD patients with S/S genotype of HO-1,
those with L/L genotype had a significantly higher prevalence
of CAD (29.1 vs 14.2%; P¼ 0.005) and cardiovascular disease
(33.5 vs 20.3%; P¼ 0.033), but similar frequencies of
hypertension, DM, cerebral infarction, and PAODs (Table 3).
Cox regression model of multivariate analysis for AVF failure
Table 4 shows the Cox regression model for the association of
AVF failure with the selected parameters carrying obvious or
borderline statistical significances from Table 1. There was a
significant correlation between increasing incidence of AVF
failure and longer HD duration, lower pump flow, higher
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Figure 1 | (a) Distribution of allele frequency of the (GT)n repeats
in all HD patients (n¼ 603), (b) HD patients without AV fistula
failure (n¼ 425), (c) those with AV fistula failure (n¼ 178),
(d) and controls (n¼ 286). There is no significant difference
between (a) and (d), but there is significant difference between
(b) and (c).
Table 2 | Comparison of HO-1 promoter genotypes and allele frequencies among controls, total and subgroups of hemodialysis
patients (with and without AVF failure)
Controls Total HD patients
HD patients without
AVF failure
HD patients with
AVF failure P-value
Alleles, n (%) n=572 n=1206 n=850 n=356
S (short) 285 (49.8%) 593 (49.2%) 441 (51.9%) 152 (42.7%) NS*
L (long) 287 (50.2%) 613 (50.8%) 409 (48.1%) 204 (57.3%) 0.004#
Genotypes, n (%) n=286 n=603 n=425 n=178
S/S 61 (21.3%) 148 (24.5%) 118 (27.8%) 30 (16.8%) NS*
L/S 163 (57%) 297 (49.3%) 205 (48.2%) 92 (51.7%) 0.011#
L/L 62 (21.7%) 158 (26.2%) 102 (24%) 56 (31.5%)
The alleles were classified into two subgroups according to the number of GT repeats: the S group with repeat number o30, and the L group with X30 GT repeats; the
genotypes were classified into three subgroups according to the number of GT repeats at both chromosomes: the S/S group with both repeat numberso30, L/S group with
one repeat numbero30 and one repeat numberX30, and L/L group with both repeat numbersX30. NS=nonsignificant. *Signifies the P-value for the comparison between
controls and HD patients; #signifies the P-value for the comparison between HD patients with and without AVF failure.
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dynamic venous pressure, location of AVF at the right side and
upper arm, and L/L and L/S genotypes of HO-1. HO-1
genotype polymorphism was a strongly relevant factor and
showed a significant difference, with a hazard ratio of 2.040 and
a 95% confidence interval between 1.295 and 3.215 (P¼ 0.002).
Relative incidence of AVF failure and HO-1 genotypes
Some patients experienced multiple episodes of AVF failure
during observation. Thus, HO-1 genotypes and the relative
incidence of AVF failure (number of incidences per patient-
months of follow-up) were calculated. Table 5 lists the
relative incidence of AVF failure in HD patients according to
the three different HO-1 genotypes. Relative incidences were
1 episode per 87.6 patient-months, 1 episode per 129 patient-
months, and 1 episode per 224.9 patient-months for HD
patients with L/L, L/S, and S/S genotypes, respectively. The
relative incidence in the subgroup of L/L genotype (1 episode
per 87.6 patient-months) was significantly greater than that
in the subgroup of S/S genotype (1 episode per 224.9 patient-
months; Po0.002; Table 5).
Relationship between the HO-1 genotype and AVF patency
Of the 148 patients with S/S genotypes, fistula failure occurred
in 30 patients after 46.4754.3 months, whereas the remaining
118 patients without fistula failure were followed for
65.1754.2 months (P¼ 0.09). Among the 297 HD patients
with L/S genotypes, 92 patients developed AV fistula failure
after a mean time of 37.2745.2 months. The remaining 205
patients without fistula failure were followed for 63.2753.6
months (Po0.001). Among the 158 patients with L/L
genotypes, 56 patients had fistula failure that occurred after
35.0754.1 months. The 102 patients who had no fistula
failure had a mean follow-up of 65.7750.4 months
(Po0.001). The time of follow-up in patients without fistula
failure did not differ significantly among the three genotype
subgroups (S/S, L/S, and L/L). We evaluated the effect of
different genotypes of HO-1 on AVF patency for all the HD
patients in this study. As shown in Figure 2, AV fistula patency
differed significantly when patients were classified according
to their HO-1 genotypes. The unassisted patency of AV fistulae
at 5 years decreased significantly from 83.8% (124/148) in
patients with S/S genotypes to 75.1% (223/297) in patients
with L/S genotypes and further to 69% (109/158) in patients
with L/L genotypes (Po0.0001 by log-rank test; Figure 2).
DISCUSSION
According to the recommendation of the Disease Outcomes
Quality Initiative (DOQI) guidelines, creation of native AV
fistulas at the upper extremity is preferable to placement of
AV graft account of lower morbidity and higher long-term
patency. Nevertheless, stenosis remains the most frequent
complication for native AV fistulas and may predispose to
Table 4 | Cox regression model of factors associated with AVF
failure in HD patients
Significance
Hazard
ratio
95% CI
lower
95% CI
upper
HD duration (months) 0.006 1.004 1.001 1.008
Pump flow (ml/min) 0.006 0.993 0.988 0.998
Maximal venous pressure
(mmHg)
o0.001 1.010 1.004 1.015
Right vs left side 0.005 1.587 1.147 2.197
Upper arm vs forearm o0.001 2.242 1.557 3.228
HO-1 genotype (L/L+L/S vs S/S) 0.002 2.040 1.295 3.215
Cardiovascular disease 0.224 1.424 0.805 2.517
Hypertension 0.858 0.945 0.507 1.760
Table 5 | HO-1 genotypes and relative incidence of AVF
failure in HD patients
Genotype
Total observations
(patient-months)
Episodes
(times)
Episodes/patient-
months
S/S 10794.7 48 1/224.9
Po0.002S/L 20513.6 159 1/129.0
L/L 11035.2 126 1/87.6
Total 42343.5 333 1/127.2
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Figure 2 | Five-year unassisted patency of AV fistula comparing
HD patients with different HO-1 genotypes (S/S, L/S, L/L);
Po0.0001 for the comparison between the three survival curves.
Table 3 | HO-1 genotypes and vascular diseases in hemodia-
lysis patients
Genotype, case number (n)
S/S
n=148
L/S
n=297
L/L
n=158 P-value
Hypertension (%) 51.4 52.9 54.4 NS
Diabetes mellitus (%) 25.7 31.6 32.9 NS
Cerebral infarction (%) 7.4 9.8 7.6 NS
Peripheral arterial
obstructive disease (%)
3.4 4.7 5.7 NS
Coronary artery disease (%) 14.2 20.2 29.1 0.005
Cardiovascular disease (%) 20.3 27.3 33.5 0.033
AVF failure (%) 20.3 31.0 35.4 0.011
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thrombosis and subsequent AVF failure. In this study, both
univariate and multivariate analyses showed that the presence
of AVF failure could be significantly correlated with several
clinical factors, including HD duration, location of AV fistula
at the upper arm (cephalic vein-to-brachial artery anasto-
mosis) or right upper extremity, and dynamic venous
pressure. As to the preferable location of vascular access,
usually the first native AV fistula will be created at the
forearm of the nondominant hand. Since more than 95% of
our HD patients use the right hand as their dominant hand,
the desirable location of AVF placement should be the left
forearm (brachiocephalic vein-to-radial artery anastomosis at
wrist). Henceforth, the generalized vascular quality was
usually poorer in these HD patients, with location of their
first AVF at the upper arm (cephalic vein to brachial artery at
elbow) or right side because a suitable vein for the creation of
AVF was not available at the left forearm. It is reasonable that
HD patients with poorer vascular condition may also have
higher risk of AVF failure. Patients with AVF stenosis usually
have a higher dynamic venous pressure than those without
stenosis. From univariate analysis, hypertension was a signi-
ficant factor in decreasing the frequency of AVF failure.
As we know, hypotension may increase the risk of access
failure because reducing Qa may predispose to clotting in a
dialyzer. HD patients with hypertension should be less prone
to hypotension, and therefore may have a lower prevalence of
AVF failure than those without hypotension. In comparison
with HD patients without hypertension, however, those with
hypertension had a lower frequency of location of AVF at the
upper arm (11.9 vs 18.2%, Po0.05). As location of AVF at
the upper arm is a risk factor of AVF failure by our results, its
lower frequency might reduce the risk of AVF failure in those
with hypertension. Therefore, hypertension was no more
significant in reducing the frequency of AVF failure after the
confounding effect of AVF location was removed by multi-
variate analysis. On the contrary, maximal pump flow was
not significant in univariate analysis, but was significant in
multivariate analysis, which might be caused by higher
prevalence of location of AVF at the upper arm in those with
AVF failure. The Qa of AVF at the upper arm is usually higher
than that of AVF at the forearm. A higher Qa usually permits
a higher maximal pump flow. Consequently, the maximal
pump flow may increase more in those with AVF failure than
in those without AVF failure under the above-mentioned
confounding effect between these variables. After adjusting
for the confounding effect arising from location of AVF at the
upper arm, maximal pump flow was significantly lower in
those with AVF failure by multivariate analysis.
In our study, both older age and a history of diabetes
mellitus (DM) were not significant risk factors for AVF failure,
which is similar to the results of some large-scale single-center16
and multi-center8,17 studies on AVF survival. Only a few earlier
single-center studies, including smaller case numbers, reported
a significantly reduced AVF survival in HD patients with old
age or DM.18 However, these two characteristics were risk
factors for failure of synthetic AV grafts in HD patients.17
Moreover, our study revealed that there was no correlation
between cardiovascular disease and AVF failure, which is
similar to the studies reporting no association of AVF failure
with a history of any vascular disease, including CAD,8,19
cerebral vascular disease,8 or peripheral vascular disease.19
Cardiovascular diseases are more greatly characterized by
inflammatory response and endothelial dysfunction than AVF
stenosis. In addition, the main pathological feature of AVF
stenosis is intimal hyperplasia, which is different from the
atherosclerotic lesions specific to cardiovascular diseases.
Although the above-mentioned risk factors of AVF failure
have been identified in this study, stenosis still develops with
wide individual variation. As the stenotic lesions are character-
ized by intimal hyperplasia originating from VSMC migration,
proliferation, and exuberant synthesis of extracellular matrix,20
some factors (such as TGF-b and homocysteine) were
associated with these pathologic characteristics. Further,
according to the genetic reports by Heine et al.7 and Fukasawa
et al.,8 genotype polymorphisms of TGF-b and MTHFR are
independent factors for predicting AVF stenosis and patency.
We investigated HO, another genetic factor other than
TGF-b and homocysteine, possibly contributing to the
pathophysiologic features of AVF stenosis.
HO catalyzes the rate-limiting step in the degradation of
heme by cleaving the a-meso carbon bridge of heme, leading
to the generation of equimolar quantities of CO, free iron,
and biliverdin.21 There are three isoforms of HO: (i) HO-1,
an inducible 32-kDa protein, is ubiquitously distributed, and
its encoding gene is located at chromosome 22q12;11 (ii) HO-2,
a constitutively expressed 36-kDa protein, is present in high
levels in the brain and testes, and its encoding gene is located
at chromosome 16p13.3; (iii) HO-3 is a 33-kDa protein
resembling HO-2, but with lower catalytic activity. HO-1 is a
stress-responsive protein that can be induced by various
oxidative agents, including heavy metals, inflammatory media-
tors, ultraviolet radiation, endotoxin, heme, and hemoglobin.22
Moreover, HO-1 plays an important role in growth regulation,
cell proliferation, cell death (apoptosis), and cell hypertrophy.
HO-1-derived CO may act in three ways to regulate the
function and numbers of cells in vascular walls.10 First, it can
work as an autocrine factor to inhibit VSMC proliferation by
blocking cells in the G0/G1 phase of the cell cycle.
10 Second,
the release of CO from luminal VSMCs can function in a
paracrine manner to inhibit the release of vascular mitogens
from circulating platelets and adjacent endothelial cells.
Third, HO-1-mediated release of CO, in an endocrine-like
fashion, may participate in the process of ‘re-endothelializa-
tion of the vessel wall’ at sites of vascular injury by
stimulating growth and preventing apoptosis of endothelial
cells. Through the combination of the above-mentioned
effects, VSMC proliferation is inhibited further, as several
antiproliferative factors, including nitric oxide and heparan
sulfate proteoglycan, can be released from endothelial cells.23
Finally, the HO-1-catalyzed production of biliverdin and
bilirubin may aggravate the loss of VSMCs in injured vascular
walls by prompting VSMC apoptosis.24
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Augmented synthesis of CO after upregulation of HO-1 gene
expression will inhibit the proliferation of VSMC through the
following mechanisms:10 (i) enhancing expression of cyclic 30,50
guanosine monophosphate by increasing the activity of
guanylate cyclase; (ii) arresting VSMCs in G1/S phase of the
cell cycle; (iii) decreasing the expression of cyclin A mRNA,
leading to downregulation of cyclin A-associated kinase and cdk-
2 activity, which are key regulators of both G1- and S-phase cell
progression; (iv) enhancing the activity of p21, which is a cyclin-
dependent kinase inhibitor; (v) lowering the release of
endothelin-1 and platelet-derived growth factor from endothelial
cells; (vi) inhibiting platelet aggregation; and (vii) incremental
synthesis of bilirubin inhibiting monocyte transmigration and
leukocyte adhesion induced by oxidized LDL or other oxidants.25
Dinucleotide repeat (GT)n, the most frequent simple repeat
in the human genome, is usually characterized by length
polymorphism and may modify gene transcription.26 A (GT)n
dinucleotide repeat was located in the proximal promoter region
HO-1 gene, which was mapped at chromosome 22q12.11,27 It is
suggested that the highly polymorphic (GT)n repeat in the HO-1
gene could alter transcriptional activity. Chen et al.13 showed
that the more the (GT)n repeats in the promoter region, the
less the transcription of the HO-1 gene by using HO-1
promoter/luciferase reporter genes carrying different lengths
of (GT)n repeats in rat aortic smooth muscle cells. This result
is in accord with that shown earlier in Hep3B cells.
In this study of 603 HD patients, we analyzed the
correlation between AVF failure and the dinucleotide length
polymorphism (GT)n in the HO-1 gene promoter. There was
no difference in primary diseases between the HO-1 genotype
groups. The frequencies of DM and hypertension, suspected
to have a correlation with vascular disease, were similar among
the three patient groups with different HO-1 genotypes.
However, the proportion of AVF failure increased from 20.3%
in group S/S to 31.0% in group L/S and 35.4% in group L/L
(P¼ 0.011). A similar trend of frequency increase from the
HO-1 genotype group S/S to L/S to L/L could also be found
for CAD and cardiovascular disease, but not for peripheral
artery obstructive disease (PAOD) or cerebral infarction.
Recently, the role of the dinucleotide repeat length
polymorphism of the HO-1 gene promoter has been reported
in several human vascular diseases. Emerging evidence shows
that a longer (GT)n repeat in the promoter region of the HO-1
gene is associated with (i) restenosis and increased vascular
inflammation after percutaneous transluminal angioplasty28
(odds ratio¼ 5 for (GT)nX25 vs (GT)no25), (ii) suscept-
ibility to CAD in Japanese patients with coronary risk
factors12 (odds ratio¼ 2.5–4.8 for (GT)n427 vs (GT)np27),
and (iii) the development of abdominal aortic aneurysms29
(odds ratio¼ 1.9 for (GT)nX25 vs (GT)no25). It was shown
that a longer (GT)n repeat was associated with emphysema in
smokers (odds ratio¼ 4.2 for (GT)nX30 vs (GT)no30).15
Chen et al.13 further reported that type II diabetics carrying
longer (GT)n repeats may have higher oxidative stress and
increased susceptibility to the development of CAD (odds
ratio¼ 4.7 for (GT)nX32 vs (GT)no32). As excessive growth
of VSMCs is an important contributing factor to a number of
vascular disease states such as restenosis following angio-
plasty,30 atherosclerosis,31 and hypertension,32 increasing
HO-1 expression in blood vessels may offer a promising
approach in treating these vascular disorders.
The absence of significant difference in HO-1 genotype
frequency between HD patients and healthy controls in our
study may result from the following reasons. First, the
development of end-stage renal disease (ESRD) is associated
with various causes and risk factors, including susceptibility
factors (such as older age and family history of ESRD),
initiation factors (such as DM, hypertension, nephrotoxic
medications, etc.), and progression factors (such as proteinur-
ia, poorly controlled blood pressure and glucose, smoking,
etc.). All these factors may play more important roles than
HO-1 in the development of ESRD. Second, the protective
effect of HO-1 on renal injury has been reported mainly in
hematuric renal disease33 and acute renal failure induced by
various factors (such as cisplatin, mercury, myoglobulin,
etc.).34–36 However, most cases of ESRD result from
nonhematuric chronic kidney diseases (such as hypertension
and diabetes). Third, HO-1 overexpression may worsen renal
injury. Suttner et al.37 found that low levels (two- to five-fold
that of control) of HO-1 expression are protective, whereas
high (415-fold) levels of HO-1 expression actually worsen the
damage. This damage may derive from greater elevations of
intracellular free iron produced by overexpressed HO-1 gene.
In this investigation, we studied the association of AVF
failure with HO-1 genotype polymorphisms. However, many
factors may predispose HD patients to AVF failure: (i)
technique of the vascular surgeon; (ii) endothelial dysfunction
and shear stress under excessive extracorporeal blood flow;
(iii) vascular injury on account of frequent puncture; (iv)
prolonged external compression after HD; (v) reduced Qa
(frequent hypotension in association with HD or insufficient
dilatation due to poor vascular anatomy); and (vi) hypercoa-
gulable status due to the presence of factors for thrombophi-
lia, such as factor V Leiden, prothrombin gene mutation
(G20210A), factor XIII genotype (Val34Leu), MTHFR
(C677T) genotype T/T, and higher concentrations of lupus
anticoagulant, anticardiolipid antibody, factor VIII, homo-
cysteine, and lipoprotein (a).38 A sudden onset of AVF failure
may develop in some patients, without previous appearance
of elevated venous pressure or insufficient extracorporeal
blood flow. The possibility of coagulation abnormality or
another cause of AVF failure must be taken into account.
In the present investigation, we focused on the dinucleo-
tide length polymorphisms of HO-1. There was a significant
difference between S/S, L/S, and L/L genotypes by patient
number and incident episodes (per patient-month). Here,
HO-1 genotype polymorphisms (class L/S and L/L) were
proved to be associated with a higher failure frequency as well
as a shorter patency of AVF in HD patients.
We acknowledge that some limitations should be
considered in the interpretation of this study result. First,
all our study subjects are Chinese living in Taiwan, so the
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characteristic of distinct ethnicity may prevent the results of
this study from being extrapolated to other ethnic groups.
Second, the association may not be present for other types of
vascular access, such as AV graft, because our result comes
from patients with AV fistulae. Third, a selection bias might
exist because this study is based on a retrospective cohort
study. Only those who survived at the time of study
enrollment had the opportunity of being selected and of
receiving venous sampling; all those who had dropped out
from maintenance HD treatment would be excluded from
this study. The selection bias may be avoided by conducting a
randomized prospective cohort study.
In conclusion, stenosis-related AVF failure remains a major
clinical problem although the programs for regular monitoring
and surveillance of AVF are encouraged. Recently, there is
increasing evidence that genetic background may explain at least
part of the excessive risk for stenosis observed in certain HD
patients. In this study, for the first time, we demonstrated that
genotype polymorphisms in the promoter of HO-1 gene may be
associated with stenosis-related AVF failure in HD patients. The
long dinucleotide GT repeat in the promoter region may
diminish HO-1 gene transcription, and consequently offset the
protective effect (through CO) against vascular injury. More
studies are needed to investigate whether selective pharmaco-
logical regulation of HO-1 activity in the subgroup carrying
higher risk will improve AVF function or reduce the frequency
of AVF failure for HD patients in the future.
MATERIALS AND METHODS
Study population
In this study, we screened all patients undergoing maintenance HD
therapy at four institutions – Taipei Veterans General Hospital, Shin-
Jen HD Center, Hwa-Jong HD Center, and Wen-Lin HD Center –
between January and March 2005, for whom medical records and
blood samples for genotyping were available. We included patients
in this study if they met the following criteria: (1) creation of a
native AV fistula as the first vascular access for HD between January
1, 1980 and December 31, 2004; (2) creation of AV fistula by similar
surgical skills with end-to-side anastomosis at the upper extremity
and (3) receiving HD therapy for 4 h three times weekly for more
than 3 months. Patients were excluded if they fulfilled one of the
following criteria: (1) receiving an AV graft as the first vascular
access and (2) the first episode of fistula failure or interventional
procedure did not result from stenosis-related events, such as
infectious complication, progressive aneurysmal formation, or steal
syndrome. We also included 286 healthy men (n¼ 179) and women
(n¼ 107) without renal disease as controls. This retrospective study
was based on the Declaration of Helsinki (edition 6, revised 2000).39
Informed consent was obtained from all study patients and controls,
and the study was approved by the Institutional Research Board of
Taipei Veterans General Hospital. For HD patients, we recorded the
following clinical factors: age (at HD therapy initiation and at the
beginning of the study), gender (HD therapy duration), side (right
or left) and location (elbow or wrist) of the first created native AV
fistula, underlying cause of end-stage renal disease (presence or
absence of diabetic nephropathy), time of AV fistula failure, peak
dynamic venous pressure, and maximally delivered extracorporeal
blood flow during the 30 days prior to AVF failure or the date of
termination of observation. We also recorded the history of the
following vascular diseases: presence of hypertension, presence of
PAOD, presence of cerebrovascular disease (CVD), and presence of
CAD prior to AVF failure for those with fistula failure or until
March 31, 2005 for those without AVF failure. The primary end
point was unassisted patency, which was defined as the time from
fistula surgery to the first episode of fistula failure for patients
meeting the inclusion criteria and without the presence of any
exclusion criteria. We defined fistula failure as the need for any
interventional procedure (surgery or angioplasty) to correct a
malfunctioning or occlusive fistula, which appeared at least 3
months after fistula surgery. Fistula failure within the first 3 months
after fistula construction was regarded as inadequate dilatation
rather than intimal hyperplasia; so the appropriate timing for
cannulation was 3–4 months after placement of AVF, as suggested by
DOQI guidelines.40 These patients were excluded from our analysis.
Patients were assessed at the time of renal transplantation (n¼ 1),
death with a functioning access (n¼ 3), shifting to peritoneal
dialysis (n¼ 2), or loss to follow-up (n¼ 6). This observation study
was terminated on March 31, 2005.
Assessment of comorbid vascular diseases
PAOD was defined as having undergone peripheral bypass surgery,
nontraumatic amputation of extremity, and angioplasty for
peripheral arteries. CVD was established by a history of carotid
endarterectomy or carotid angioplasty, a history of cerebral
infarction, or a history of carotid artery stenosis with imaging
diagnosis (Doppler scan of carotid arteries, computed tomography,
or magnetic resonance imaging of brain). This study excluded
patients who had lacunar infarctions without apparent symptoms.
CAD was diagnosed from medical records (history of coronary
artery angioplasty or coronary artery bypass graft surgery, history of
myocardial infarction, or a confirmatory coronary angiography by
the medical doctor of each institute). Cardiovascular disease was
defined as having a history of PAOD, CVD, or CAD.
Determination of length polymorphism of (GT)n repeats in
HO-1 gene promoter
Peripheral blood without dietary control during voluntary HD was
collected in a tube containing ethylenediamine tetraacetate (EDTA)-
2K and immediately subjected to genomic DNA extraction
procedures. Genomic DNA was isolated using the Puregene DNA
purification kit (Gentra, Minneapolis, MN). The (GT)n repeat at the
promoter region of the HO-1 gene was amplified by polymerase
chain reaction (PCR) with an FAM-labeled sense primer 50-AGA
GCCTGCAGCTTCTCAGA-30, and an antisense primer 50-ACAAA
GTCTGGCCATAGGAC-30, according to Kimpara et al.,41 in a
7.5 ml PCR reaction containing 7.5 ng of genomic DNA, 0.333 mM
of each primer, 1.5 mM MgCl2, and 0.1875 U of Taq DNA
polymerase (Amersham Biosciences, GE Healthcare, Sunnyvale,
CA) in 200 mM of dNTPs and 1 PCR buffer supplied with the
enzyme. The PCR conditions consisted of an initial denaturation at
941C for 3 min, followed by 30 cycles of denaturation at 941C for
1 min, annealing at 551C for 1 min, extension at 721C for 1 min, and
a final extension at 721C for 60 min on MJ Research PTC-100
thermal cyclers (MJ Research Inc., Watertown, MA) or ABI PRISM
9700/2700 thermal cyclers (Applied Biosystems, Foster City, CA).
The diluted PCR products with internal size standard, MegaBACEt
ET400-R (Amersham Biosciences, GE Healthcare, Sunnyvale, CA),
were analyzed using an ABI PRISM 377 automated DNA sequencer
(Applied Biosystems) and GeneScan software (version 2.1) (Applied
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Biosystems). The GT-repeat length was determined and statistically
analyzed using the Genotyper (version 2.0) program (Applied
Biosystems). All fragment analyses contained appropriate negative
and positive controls.
Statistical analysis
Data management and statistical analysis were carried out using the
SPSS statistical software (version 11.0; USA). Distributions of
continuous variables in groups were expressed as mean7s.d. and
compared by Student’s t-test. All data were tested for normal
distribution before using t-tests. Categorical variables, such as the
distribution of genotype frequencies in patients and controls, were
analyzed by the w2 test. The Cox regression model was used to adjust
for other established risk factors of AV fistula stenosis. Adjusted odds
ratio and 95% confidence interval for every explanatory variable were
also calculated. Survival curves of unassisted patency of AV fistula
were calculated by the Kaplan–Meier method and compared by the
log-rank test. Po0.05 was considered to be statistically significant.
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